United Therapeutics
UTHR
374 hedge funds and large institutions have $4.88B invested in United Therapeutics in 2018 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 128 increasing their positions, 154 reducing their positions, and 52 closing their positions.
0.3% less ownership
Funds ownership: 101.03% → 100.73% (-0.3%)
2% less call options, than puts
Call options by funds: $22.3M | Put options by funds: $22.8M
7% less funds holding
Funds holding: 400 → 374 (-26)
17% less repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 154
24% less capital invested
Capital invested by funds: $6.44B → $4.88B (-$1.56B)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
35% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$72M |
| 2 |
KAM
Krensavage Asset Management
New York
|
+$45.7M |
| 3 |
JP Morgan Chase
New York
|
+$29M |
| 4 |
AC
Armistice Capital
New York
|
+$23.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$60.7M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$37.5M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$36.7M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$25.8M |
| 5 |
D.E. Shaw & Co
New York
|
-$24M |
UTHR Hedge Fund Activity: Q1 2018 in Review
374 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2018, worth a combined $4.88B — down 24% from $6.44B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of UTHR and 34 opened new positions — a net loss of 18 holders — while 154 trimmed existing stakes and 128 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $72M. The largest seller was Schroder Investment Management Group, cutting an estimated $60.7M.
- 374 institutional investors held United Therapeutics (UTHR) as of Q1 2018, down from 400 in Q4 2017.
- Funds reported $4.88B of United Therapeutics stock for Q1 2018, down 24% quarter-over-quarter.
- 34 funds opened new United Therapeutics positions in Q1 2018 and 52 closed out, a net change of -18 holders.
- The largest United Therapeutics buyer in Q1 2018 was Consonance Capital Management, an estimated $72M added.
- The largest United Therapeutics seller in Q1 2018 was Schroder Investment Management Group, an estimated $60.7M sold.
Based on aggregated 13F filings for Q1 2018.